Twist Bioscience (TWST) to Release Earnings on Monday

Twist Bioscience (NASDAQ:TWST) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Monday, May 5th. Analysts expect Twist Bioscience to post earnings of ($0.56) per share and revenue of $92.00 million for the quarter. Twist Bioscience has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same period in the previous year, the firm earned ($0.75) earnings per share. Twist Bioscience’s revenue for the quarter was up 24.1% compared to the same quarter last year. On average, analysts expect Twist Bioscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Twist Bioscience Trading Up 4.1 %

NASDAQ:TWST opened at $39.24 on Friday. The stock has a fifty day simple moving average of $39.24 and a 200 day simple moving average of $44.07. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $2.34 billion, a price-to-earnings ratio of -11.61 and a beta of 2.34. Twist Bioscience has a 1-year low of $33.16 and a 1-year high of $60.90.

Insiders Place Their Bets

In related news, CEO Emily M. Leproust sold 5,200 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $256,620.00. Following the transaction, the chief executive officer now directly owns 667,318 shares in the company, valued at approximately $32,932,143.30. This trade represents a 0.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Patrick John Finn sold 2,058 shares of the company’s stock in a transaction dated Wednesday, April 23rd. The shares were sold at an average price of $39.99, for a total transaction of $82,299.42. Following the sale, the chief operating officer now owns 265,460 shares of the company’s stock, valued at $10,615,745.40. This trade represents a 0.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,432 shares of company stock valued at $1,038,170 over the last 90 days. 3.01% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

TWST has been the subject of several research analyst reports. Barclays reduced their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Robert W. Baird upped their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. Finally, Guggenheim set a $50.00 target price on shares of Twist Bioscience in a research note on Friday, March 28th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.